{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:11:50Z","timestamp":1776229910683,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to explore the effect of prostate-specific membrane antigen (PSMA) positron emission tomography and computed tomography (PET\/CT) on clinical TNM (cTNM) staging assessment and treatment decision-making in prostate cancer,providing real-world evidence for its clinical application in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical data of 125 prostate cancer patients who underwent PSMA PET\/CT at Chongqing University Cancer Hospital from January 2019 to June 2022. The results were compared with traditional imaging methods (bone scan, CT, MRI) in the overlapping subset of patients with both examinations to assess changes in TNM staging and treatment plans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSMA PET\/CT, TNM staging changed in 48 patients (38.40%), particularly in the primary prostate cancer and pre-radical surgery groups regarding regional lymph node detection (P\u00a0=\u00a00.007, P\u00a0=\u00a00.040). CTNM staging was revised in 36 patients (28.80%), most significantly in the post-radical surgery and mCRPC groups (47.06% and 55.88%, respectively; P\u00a0=\u00a00.036, P\u00a0=\u00a00.000). Changes in treatment plans did not reach statistical significance for newly diagnosis of Prostate and pre-radical surgery group (P\u00a0=\u00a00.222,P= 0.151).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PSMA PET\/CT significantly impacts cTNM staging assessment and treatment decisions in prostate cancer, offering precise evaluation and auxiliary diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1756827","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:37:30Z","timestamp":1776227850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real world report: PSMA-PET\/CT-guided TNM restaging and its consequences for treatment planning in prostate cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Han","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urologic Oncology Surgery, Chongqing University Cancer Hospital (Chongqing Cancer Institute & Chongqing Cancer Hospital)","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology Surgery, Chongqing University Cancer Hospital (Chongqing Cancer Institute & Chongqing Cancer Hospital)","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology Surgery, Chongqing University Cancer Hospital (Chongqing Cancer Institute & Chongqing Cancer Hospital)","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology Surgery, Chongqing University Cancer Hospital (Chongqing Cancer Institute & Chongqing Cancer Hospital)","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"JNCC"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513\u2013025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112594","article-title":"PSMA PET\/CT in the diagnosis and staging of prostate cancer","volume":"12","author":"Combes","year":"2022","journal-title":"Diagn (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ro.2021.08.006","article-title":"Prostate-specific membrane antigen (PSMA) PET: A counterpart to prostate MRI","volume":"56","author":"Chen","year":"2021","journal-title":"Semin Roentgenol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061108","article-title":"Biomarkers in prostate-specific membrane antigen theranostics","volume":"11","author":"Vlachostergios","year":"2021","journal-title":"Diagn (Basel)"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"B8","first-page":"574.e19","article-title":"68Ga-PSMA PET\/CT: Does it predict adverse pathology\u00a0findings at radical prostatectomy","volume":"37","author":"Dekalo","year":"2019","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112330-20210714-00368","article-title":"Comparison of the diagnostic value of 18F-PSMA PET\/CT and mpMRI for pelvic lymph node metastasis in prostate cancer","volume":"43","author":"Liu","year":"2022","journal-title":"Chin J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112330-20200624-00491","article-title":"Application of 68Ga-PSMA PET\/CT in preoperative diagnosis and surgical strategy formulation in prostate cancer","volume":"42","author":"Li","year":"2021","journal-title":"Chin J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262398","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold\u00a0standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: Results from a prospective single-center imaging trial","volume":"63","author":"Sonia","year":"2022","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737989","article-title":"Head-to-head comparison of 68Ga-PSMA-11PET\/CT and multiparametric MRI for pelvic lymph node staging prior to radical prostatectomy in patients with intermediate to high-risk prostate cancer: A meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.27323","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 99mTc-MDP bone scintigraphy for the detection of bone metastases in patients with prostate cancer: A meta-analysis","volume":"219","author":"Zhao","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13595","article-title":"68Ga-prostate-specific membrane antigen (PSMA) PET\/CT as a clinical decision-making tool in biochemically recurrent prostate cancer","volume":"18","author":"Davies","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.211086","article-title":"68Ga-PSMA-11 PET\/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients","volume":"60","author":"Koerber","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:37:47Z","timestamp":1776227867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1756827"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1756827","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1756827"}}